Cited 0 times in
Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김준원 | - |
dc.contributor.author | 김지형 | - |
dc.contributor.author | 배숭준 | - |
dc.contributor.author | 안성귀 | - |
dc.contributor.author | 이익재 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 조연아 | - |
dc.date.accessioned | 2024-04-11T06:30:46Z | - |
dc.date.available | 2024-04-11T06:30:46Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198808 | - |
dc.description.abstract | Purpose: This study aimed to assess the feasibility and safety of administering intraoperative radiotherapy (IORT) as a boost dur ing breast-conserving surgery (BCS) following neoadjuvant chemotherapy for patients at high risk of breast cancer recurrence. Materials and Methods: Patients who underwent neoadjuvant chemotherapy received a single 20-Gy dose of IORT during BCS, followed by external beam radiotherapy 4–6 weeks after surgery. Results: The median follow-up duration was 31.0 months (range, 18.0–59.0 months). Initial tumor sizes had a median of 2.6 cm (range: 0.8–5.3 cm), reducing to 0.3 cm (range: 0–4.0 cm) after neoadjuvant chemotherapy. The most common neoadjuvant che motherapy regimen was doxorubicin and cyclophosphamide, followed by paclitaxel (n=42, 73.7%). Among 57 patients who re ceived neoadjuvant chemotherapy before BCS and IORT, 2 patients (3.5%) required secondary surgery to achieve negative resec tion margins due to initially positive margins. Regional lymph node irradiation was performed in 37 (64.9%) patients. There was no grade 3 or higher adverse events, with 4 patients (7.0%) experiencing grade 2 acute radiation dermatitis and 3 (5.3%) having less than grade 2 breast edema. Binary correlation analysis did not reveal statistically significant associations between applicator size or radiation therapy modality and the risk of treatment-related toxicity. Furthermore, chi-square analysis showed that the grade of treatment-related toxicity was not associated with the fractionated regimen (p=0.375). Conclusion: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Breast Neoplasms* / drug therapy | - |
dc.subject.MESH | Breast Neoplasms* / radiotherapy | - |
dc.subject.MESH | Breast Neoplasms* / surgery | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Feasibility Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mastectomy, Segmental | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local / pathology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Radiotherapy Dosage | - |
dc.title | Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Gowoon Yang | - |
dc.contributor.googleauthor | Jun Won Kim | - |
dc.contributor.googleauthor | Ik Jae Lee | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Sung Gwe Ahn | - |
dc.contributor.googleauthor | Soong June Bae | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Yeona Cho | - |
dc.identifier.doi | 10.3349/ymj.2023.0229 | - |
dc.contributor.localId | A00958 | - |
dc.contributor.localId | A00999 | - |
dc.contributor.localId | A05345 | - |
dc.contributor.localId | A02231 | - |
dc.contributor.localId | A03055 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A04680 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 38373832 | - |
dc.subject.keyword | Breast neoplasms | - |
dc.subject.keyword | intraoperative | - |
dc.subject.keyword | neoadjuvant therapy | - |
dc.subject.keyword | radiotherapy | - |
dc.subject.keyword | safety | - |
dc.contributor.alternativeName | Kim, Jun Won | - |
dc.contributor.affiliatedAuthor | 김준원 | - |
dc.contributor.affiliatedAuthor | 김지형 | - |
dc.contributor.affiliatedAuthor | 배숭준 | - |
dc.contributor.affiliatedAuthor | 안성귀 | - |
dc.contributor.affiliatedAuthor | 이익재 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.contributor.affiliatedAuthor | 조연아 | - |
dc.citation.volume | 65 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 129 | - |
dc.citation.endPage | 136 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.65(3) : 129-136, 2024-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.